Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest

被引：3

作者：

Waites, K

Brookings, E

Nix, S

Robinson, A

Gray, B

Swiatlo, E

机构：

[1] Univ Alabama, Dept Pathol, Birmingham, AL 35233 USA

[2] Univ Alabama, Dept Med, Birmingham, AL 35233 USA

[3] Univ Alabama, Dept Hosp Labs, Birmingham, AL 35233 USA

[4] Univ Alabama, Dept Microbiol, Birmingham, AL 35233 USA

[5] Spartanburg Reg Healthcare Syst, Spartanburg, SC USA

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 1998年 / 9卷 / 04期

关键词：

Streptococcus pneumoniae; fluoroquinolones; susceptibility testing; Etest;

D O I：

10.1016/S0924-8579(97)00053-8

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Clinafloxacin, levofloxacin, sparfloxacin and trovafloxacin were tested by Etest against 188 Streptococcus pneumoniae isolates. Clinafloxacin and trovafloxacin were 2-4-fold more potent than sparfloxacin and 8-fold more than levofloxacin. Two isolates, both serotype 6, with high-level quinolone resistance (greater than or equal to 8 mu g/ml) were detected. The Etest is a practical means for determining S. pneumoniae susceptibilities to new fluoroquinolones. (C) 1998 Elsevier Science B.V. All rights reserved.

引用

收藏

页码：215 / 218

页数：4

相关论文

共 21 条

[11] Bactericidal activity of trovafloxacin (CP-99,219) [J].

Morrissey, I .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (06) :1061-1066

[12]

*NAT COMM CLIN LAB, METH DIL ANT SUSC TE

[13] Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae [J].

Pan, XS ;

Ambler, J ;

Mehtar, S ;

Fisher, LM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2321-2326

[14] ACTIVITY OF CP99,219 COMPARED WITH DU-6859A, CIPROFLOXACIN, OFLOXACIN, LEVOFLOXACIN, LOMEFLOXACIN, TOSUFLOXACIN, SPARFLOXACIN AND GREPAFLOXACIN AGAINST PENICILLIN-SUSCEPTIBLE AND PENICILLIN-RESISTANT PNEUMOCOCCI [J].

PANKUCH, GA ;

JACOBS, MR ;

APPELBAUM, PC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (01) :230-232

[15] Non-gyrA-mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae [J].

Piddock, LJV ;

Jin, YF ;

Everett, MJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (05) :609-615

[16] Levofloxacin in vitro activities bacteremic isolates of Streptococcus pneumoniae [J].

Plouffe, JF ;

Baird, I ;

Barnishan, J ;

PorterfieldBaxa, J ;

Best, M ;

Dalieh, S ;

Emerick, J ;

Fass, RJ ;

Gianakopoulos, G ;

Hackman, BA ;

Hadley, S ;

Herbert, M ;

Koletar, SL ;

Maher, W ;

Minor, JA ;

Oglevee, BA ;

Para, MF ;

Parsons, J ;

Rogers, T ;

ScottTibbs, G ;

Tumbleson, CS .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1996, 25 (01) :43-45

[17] The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria [J].

Sefton, AM ;

Maskell, JP ;

Rafay, AM ;

Whiley, A ;

Williams, JD .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :57-62

[18] Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae [J].

Thomson, KS ;

Chartrand, SA ;

Sanders, CC ;

Block, SL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :478-480

[19] Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci [J].

Trautmann, M ;

Ruhnke, M ;

Borner, K ;

Wagner, J ;

Koeppe, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :776-779

[20] Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and pencillin-resistant pneumococci by time-kill methodology [J].

Visalli, MA ;

Jacobs, MR ;

Appelbaum, PC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (01) :77-84